CG Oncology (CGON) Change in Acquisitions & Divestments (2023 - 2026)

CG Oncology has reported Change in Acquisitions & Divestments for 4 years, with the latest figure at $252.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 26.34% year-over-year to $252.9 million; the trailing twelve-month figure through Mar 2026 stood at $896.9 million (up 12.15% YoY), and the FY2025 full-year result was $844.1 million, up 13.24% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $252.9 million, up from $222.2 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $252.9 million in Q1 2026, with the low at $30.7 million in Q3 2023.
• Historically, Change in Acquisitions & Divestments has averaged $191.2 million across 4 years, with a median of $201.2 million in 2024.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments soared 556.36% — and 2025, when it decreased 2.6%.
• CG Oncology's Change in Acquisitions & Divestments stood at $230.0 million in 2023, then declined by 0.81% to $228.2 million in 2024, then dropped by 2.6% to $222.2 million in 2025, then climbed by 13.77% to $252.9 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $252.9 million (Q1 2026), $222.2 million (Q4 2025), and $251.4 million (Q3 2025), per Business Quant data.